<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CA00959E-F4A7-46D1-B7C7-B8D837D83839"><gtr:id>CA00959E-F4A7-46D1-B7C7-B8D837D83839</gtr:id><gtr:name>Vitaflo International</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Inst of Molecular &amp; Cellular Biology</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CA00959E-F4A7-46D1-B7C7-B8D837D83839"><gtr:id>CA00959E-F4A7-46D1-B7C7-B8D837D83839</gtr:id><gtr:name>Vitaflo International</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7FF5A0AF-5490-4BC6-9152-1FE56724BB57"><gtr:id>7FF5A0AF-5490-4BC6-9152-1FE56724BB57</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Clapcote</gtr:surname><gtr:orcidId>0000-0002-6662-5690</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EC4D9D8A-B915-44F9-8253-AE6727CAFD48"><gtr:id>EC4D9D8A-B915-44F9-8253-AE6727CAFD48</gtr:id><gtr:firstName>Robert John</gtr:firstName><gtr:surname>Rodgers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900625"><gtr:id>D9588C8F-E8A0-4633-9FA4-A8FE7A9FCCF5</gtr:id><gtr:title>The Effects of Neurexin-1 Deficiency on Behavioural Phenotypes Relevant to Schizophrenia and Autism Spectrum Disorder</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900625</gtr:grantReference><gtr:abstractText>Autism spectrum disorders (ASDs) and schizophrenia are forms of mental illness that have profound, long-term impacts on the very many who will be affected in their lifetimes. Both conditions are poorly treated, in part because we know little about the root causes. However, we do know that these illnesses can be inherited, suggesting that defective genes might be involved. This project looks at one particular gene neurexin 1alpha, which was recently discovered to be damaged in some ASD and schizophrenia patients. Working out how the faulty neurexin 1alpha gene might predispose to ASD and schizophrenia is difficult because we can?t ever do the necessary studies in patients. But it turns out that a strain of laboratory mouse also has a faulty neurexin 1alpha gene that mimics the gene defect in patients. So we will use these neurexin 1alpha mutant mice to try to learn more about the role of neurexin 1alpha in ASD and schizophrenia, which might give us clues to better treatments and prevention strategies in the future.

Behavioural tests are the most appropriate for investigating the link between the faulty neurexin 1alpha gene and ASD and schizophrenia because abnormal behaviours are the primary symptoms of both disorders. While mental illnesses cannot be replicated in mice, specially-designed behavioural tests can detect behavioural abnormalities in mice that resemble human psychiatric symptoms. We will use this approach to identify the behavioural effects of the faulty neurexin 1alpha gene in mice.

At the end of this project, we expect to have identified the ASD- and schizophrenia-related behavioural changes caused by the faulty neurexin 1alpha in mice, generated evidence to help us understand the link between neurexin 1alpha gene defects and mental illness in humans, and determined whether neurexin 1alpha mutant mice exhibit a resemblance to symptoms of ASD or schizophrenia so that they can be used to investigate disease causes and novel treatments in future studies.</gtr:abstractText><gtr:technicalSummary>Autism spectrum disorders (ASDs) and schizophrenia are common, chronic mental conditions with both genetic and environmental components to their aetiology. Current drug treatments for these conditions are palliative at best, and can cause unacceptable side effects in some patients. However, the identification of genes influencing susceptibility to these disorders offers a rational route towards a clearer understanding of the neurobiology, and with this the prospect of treatment and prevention strategies tailored towards the remediation of the altered pathways.

The recent observation of hemizygous deletions eliminating the promoter and exons of neurexin 1alpha in ASD and schizophrenia patients has implicated neurexin 1alpha as a candidate gene for susceptibility to these disorders. However, the functional significance of this gene variant is poorly understood. How heterozygous disruption of neurexin 1alpha might relate to psychopathological, cognitive or biological aspects of ASD and schizophrenia remains to be clarified. Addressing these questions in patients is difficult because of the rarity of neurexin 1alpha exonic deletions, ethical limitations on clinical studies, and very limited access to human post-mortem brain tissue.

The availability of mice with deletion of the promoter and first exon of neurexin 1alpha provides direct access to the biological effects of neurexin 1alpha deficiency in the regulation of behaviours relevant to ASD and schizophrenia. We will use neurexin 1alpha mutant mice to further our understanding of the effects of variation in neurexin 1alpha gene dosage on behavioural phenotypes relevant to ASD and schizophrenia.

Behavioural assays are the most appropriate for generating biological evidence on the causal relationship between neurexin 1alpha deficiency and ASD and schizophrenia because abnormal behaviours are the primary diagnostic indicators of both disorders. While psychiatric disorders cannot be replicated in mice, fundamental symptoms can be approximated by the application of behaviourally relevant assays. We will conduct a detailed analysis of the behavioural phenotype of neurexin 1alpha mutant mice in assays designed to reflect neuropsychiatric symptoms.

At the end of this research grant, we expect to have defined the ASD- and schizophrenia-related behavioural changes caused by deletion of one or two copies of neurexin 1alpha in mice, generated biological evidence on the causal relationship between neurexin 1alpha deficiency and ASD and schizophrenia, and assessed the validity of neurexin 1alpha mutant mice as a model system for the exploration of disease mechanisms and novel treatments in future studies.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-06</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-06-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>220397</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vitaflo International</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Medium chain fatty acids as an alternative treatment to valproic acid for mania in bipolar disorder</gtr:description><gtr:id>F6B5FF4B-9429-4247-951A-0C398EFB241D</gtr:id><gtr:impact>The collaboration is multi-disciplinary, as it involves (1) behavioural neuroscience, (2) nutrition, (3) biochemistry, (4) pharmacology.</gtr:impact><gtr:outcomeId>pfxZuE6Bprv-1</gtr:outcomeId><gtr:partnerContribution>1) Financial support.

2) Nutritional supplements for testing.</gtr:partnerContribution><gtr:piContribution>1) Na+,K+-ATPase alpha3 mutant mouse model of mania.

2) Behavioural analysis of Na+,K+-ATPase alpha3 mutant mice.

3) Biochemical analysis of Na+,K+-ATPase alpha3 mutant mouse brains.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Yorkshire Post - grant report</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BC0B9BDD-F891-4128-A092-BC20F87F1F26</gtr:id><gtr:impact>Article in the Yorkshire Post reporting award of an MRC grant to study the role of neurexins in autism and schizophrenia-related behaviour.

NA</gtr:impact><gtr:outcomeId>feN1DfF3Eta</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pharmaceutical company</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>126F0DD0-C989-467F-8961-2345F8ACA115</gtr:id><gtr:impact>1.5 hour meeting with representatives from the research division of a pharmaceutical company.

Further information on the research area was passed on to the company.</gtr:impact><gtr:outcomeId>jMhfBC8Tjhg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Yorkshire Post - research report</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6E1AEF81-5317-4229-95D3-232D492D17C7</gtr:id><gtr:impact>Article in the Yorkshire Post reporting potential new drugs for mania.

NA</gtr:impact><gtr:outcomeId>XGbVMYNEbHz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Generation of mice with mutations in psychiatric disorder-associated genes, and the finding of behavioural and brain morphological abnormalities in them.</gtr:description><gtr:id>E6422FFE-90A5-4B4B-8514-E1B6F8CD4228</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>HWxrygSMis4</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Phenotypic deficits in mutant mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Generation of mutant and wildtype cDNA expression constructs for functional analysis of mutation effects.</gtr:description><gtr:id>42E065F8-A717-4B94-8576-9233FC8FCCE7</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>KMy9a6Cchkd</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mutant cDNA constructs</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D317F8E8-E389-4971-BA20-CA20ADD30C6A</gtr:id><gtr:title>Genetic suppression of agrin reduces mania-like behavior in Na+ , K+ -ATPase a3 mutant mice.</gtr:title><gtr:parentPublicationTitle>Genes, brain, and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3fbe345407fd99ccda38511c9667d1"><gtr:id>7d3fbe345407fd99ccda38511c9667d1</gtr:id><gtr:otherNames>Kirshenbaum GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1601-183X</gtr:issn><gtr:outcomeId>pm_14860_20_22520507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>680EEF98-6C0F-45DF-9249-CC9E22D08439</gtr:id><gtr:title>Characterization of cognitive deficits in mice with an alternating hemiplegia-linked mutation.</gtr:title><gtr:parentPublicationTitle>Behavioral neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3fbe345407fd99ccda38511c9667d1"><gtr:id>7d3fbe345407fd99ccda38511c9667d1</gtr:id><gtr:otherNames>Kirshenbaum GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0735-7044</gtr:issn><gtr:outcomeId>585d5668834f86.12872468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E150E01F-0E36-40C6-9384-28F8D30C7003</gtr:id><gtr:title>Heterozygous deletion of a-neurexin I or a-neurexin II results in behaviors relevant to autism and schizophrenia.</gtr:title><gtr:parentPublicationTitle>Behavioral neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8129f0b766d127dec41ec57700bc646"><gtr:id>a8129f0b766d127dec41ec57700bc646</gtr:id><gtr:otherNames>Dachtler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0735-7044</gtr:issn><gtr:outcomeId>568e826657a535.33174828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0C5726B-A39C-4DEF-824A-9E3CEBAD0E3D</gtr:id><gtr:title>Missense mutation in DISC1 C-terminal coiled-coil has GSK3? signaling and sex-dependent behavioral effects in mice.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8129f0b766d127dec41ec57700bc646"><gtr:id>a8129f0b766d127dec41ec57700bc646</gtr:id><gtr:otherNames>Dachtler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>568e82667bc332.25992445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BD0A393-0F2F-43D0-B487-E9A2EC7BDA42</gtr:id><gtr:title>The role of neurexins in schizophrenia and autistic spectrum disorder.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d6937a707cae041e0273ff9e175c561"><gtr:id>7d6937a707cae041e0273ff9e175c561</gtr:id><gtr:otherNames>Reichelt AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>gSu2t7cwP41</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD2FB18F-BF53-4766-B903-AA253BF3B21C</gtr:id><gtr:title>Disc1 deletion is present in Swiss-derived inbred mouse strains: implications for transgenic studies of learning and memory.</gtr:title><gtr:parentPublicationTitle>Laboratory animals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bec7ee04c6358a89877a491656456cb6"><gtr:id>bec7ee04c6358a89877a491656456cb6</gtr:id><gtr:otherNames>Ritchie DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0023-6772</gtr:issn><gtr:outcomeId>tSB7kBaDjWh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92F87889-E087-4461-A1B1-F51BBD2C2A9C</gtr:id><gtr:title>Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase a3 sodium pump.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3fbe345407fd99ccda38511c9667d1"><gtr:id>7d3fbe345407fd99ccda38511c9667d1</gtr:id><gtr:otherNames>Kirshenbaum GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>cjcA4PPQJvs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72CE4B31-5BFF-4761-B1AE-DC72984E8FBB</gtr:id><gtr:title>Deletion of a-neurexin II results in autism-related behaviors in mice.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8129f0b766d127dec41ec57700bc646"><gtr:id>a8129f0b766d127dec41ec57700bc646</gtr:id><gtr:otherNames>Dachtler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>doi_55f985985181810e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>074856E0-A6F1-47F4-9042-F2C1D4496885</gtr:id><gtr:title>Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17cfc5bbc1667a3216a65a4886363bcc"><gtr:id>17cfc5bbc1667a3216a65a4886363bcc</gtr:id><gtr:otherNames>McGirr A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>568e8265bbea05.67055695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD9C7251-57B8-4B37-BFBB-9B7D402AA777</gtr:id><gtr:title>Transgenic rescue of phenotypic deficits in a mouse model of alternating hemiplegia of childhood.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3fbe345407fd99ccda38511c9667d1"><gtr:id>7d3fbe345407fd99ccda38511c9667d1</gtr:id><gtr:otherNames>Kirshenbaum GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>568e8265e77ab6.05445482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A809815-9344-4DF5-9816-B93E3A57726F</gtr:id><gtr:title>Deficits in social behavioral tests in a mouse model of alternating hemiplegia of childhood.</gtr:title><gtr:parentPublicationTitle>Journal of neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3fbe345407fd99ccda38511c9667d1"><gtr:id>7d3fbe345407fd99ccda38511c9667d1</gtr:id><gtr:otherNames>Kirshenbaum GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-7063</gtr:issn><gtr:outcomeId>585d684b25d0f1.24484352</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900625</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>